US DOJ and FTC intensely scrutinise mergers in technology and pharmaceutical industries

This is an Insight article, written by a selected partner as part of GCR's co-published content. Read more on Insight

The US antitrust agencies – whose influence will soon grow thanks to revised merger guidelines – are increasingly unified in rooting out potentially anticompetitive mergers in the technology and pharmaceutical sectors.

Unlock unlimited access to all Global Competition Review content